Vernal Biosciences specializes in high-purity mRNA for research and clinical use.
Vernal Biosciences has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in June 2023.
Vernal Biosciences's investors include Alloy Therapeutics, Ampersand Capital Partners, Charles River Laboratories International, Dynamk Capital, Vermont Center for Emerging Technologies.
Vernal Biosciences is headquartered in Burlington, United States.
Vernal Biosciences specializes in high-purity mRNA for research and clinical use.
Vernal Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vernal Biosciences — Funding & Investors." VCBacked, June 27, 2023, https://www.vcbacked.co/company/vernal-biosciences. Accessed August 1, 2026.
VCBacked. (2023). Vernal Biosciences — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/vernal-biosciences
{{cite web |title=Vernal Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/vernal-biosciences |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated